RLYB - צמיחת רווחי EPS רבעונית Rallybio

Rallybio Corporation (RLYB) develops drugs for rare pathologies, ignoring macroeconomic cycles and seasonality. An elite staff of scientists is retained through stock options and scientific freedom, while orphan drug status guarantees profit protection. The growth rates of quarterly net income per share, which form this chart via GURU.Markets quotes, are currently determined by the -117.20 indicator, showing the value of this parameter.
RLYB (Rallybio): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Rallybio Corporation (RLYB) holds a patent monopoly in the orphan hematology drug segment, creating potential for a sharp surge in returns following the completion of clinical trials. The quarterly EPS trend measures the growth rate of net income per share, allowing investors to assess the real efficiency of intellectual property monetization and the business's resilience to macroeconomic slowdown.